Recombinant Human Immunoglobulin alpha Fc receptor (FCAR)

What is the molecular structure of human FCAR?

Human FCAR consists of two extracellular domains (EC1 and EC2) oriented at right angles, a transmembrane domain, and a cytoplasmic domain . The extracellular region contains two C2-type Ig-like domains that form the binding interface for IgA . The primary structure of FCAR is notably more similar to receptors in the leukocyte receptor cluster (LRC) than to other Fc receptors . The mature protein has a molecular mass of approximately 24.5 kDa, though it appears as a 28-40 kDa band on SDS-PAGE due to glycosylation . FCAR requires association with FcR γ-chain for functional signaling, as the α-chain alone cannot transmit signals effectively .

Where is FCAR expressed in human tissues?

FCAR is primarily expressed on cells of myeloid lineage, including neutrophils, eosinophils, monocytes, and macrophages . Expression patterns show tissue specificity - FCAR is notably absent from intestinal macrophages and mast cells . Circulating neutrophils express FCAR significantly, while monocytes downregulate FCAR expression as they differentiate into tissue macrophages . The receptor's expression can be modulated by cytokines, with interferon-gamma showing potential to increase Fc receptor expression on human mononuclear phagocytes .

What are the key differences between FCAR and other Fc receptors?

Unlike other Fc receptors that are encoded on chromosome 1, the FCAR gene is located on chromosome 19 within the leukocyte receptor cluster (LRC) . FCAR shows greater sequence similarity to killer cell immunoglobulin-like receptors and leukocyte Ig-like receptors than to other Fc receptors . Functionally, FCAR exhibits a unique dual signaling capacity (inhibitory or activating) depending on how IgA engages the receptor . Importantly, FCAR lacks a direct ortholog in mice, which presents challenges for research using mouse models .

How does FCAR interact with IgA molecules?

FCAR binds to the heavy-chain constant region of IgA antibodies through its EC1 domain . Up to two molecules of FCAR can bind one molecule of serum IgA . The receptor can interact with monomeric, polymeric, and secretory IgA, though with different functional outcomes . Monomeric IgA binding to FCAR typically produces transient, anti-inflammatory effects, while sustained aggregation through IgA immune complexes triggers inflammatory responses . These differential interactions form the basis for FCAR's dual functionality in immune regulation .

What is the ITAM duality concept in FCAR signaling?

FCAR demonstrates a phenomenon known as ITAM duality, where its associated immunoreceptor tyrosine-based activation motif (ITAM) can mediate either inhibitory or activating signals . Following low avidity ligand interactions (such as with monomeric IgA), FCAR induces inhibitory ITAM (ITAMi) signaling that contributes to immune homeostasis . Conversely, high avidity interactions through immune complexes trigger activating ITAM (ITAMa) signaling, leading to pro-inflammatory responses . This duality is controlled by Src family kinases and represents a sophisticated mechanism for fine-tuning IgA-mediated immune responses .

What are the downstream effects of FCAR activation in neutrophils?

When FCAR on neutrophils engages with IgA-opsonized targets (such as tumor cells), several functional outcomes occur:

• Antibody-dependent cell-mediated cytotoxicity (ADCC) against the target cell

• Release of pro-inflammatory cytokines including TNF-α and IL-1β

• Enhanced neutrophil migration to the site of activation

• Phagocytosis of IgA-opsonized particles or microbes

• Respiratory burst and release of antimicrobial compounds

These functions position FCAR as a critical mediator of neutrophil effector responses in IgA-rich environments, particularly at mucosal surfaces.

What polymorphisms exist in the FCAR gene and how do they affect function?

Several significant polymorphisms have been identified in the FCAR gene:

These genetic variations can significantly impact receptor expression and function, potentially contributing to individual differences in susceptibility to IgA-mediated diseases .

How do FCAR splice variants differ in their expression and function?

Multiple splice variants of FCAR have been reported, though only two have been confirmed at the protein level :

• a.2 form: Lacks 22 amino acids just prior to the transmembrane domain and is exclusively expressed in alveolar macrophages

• a.3 form: Lacks the EC2 domain, potentially altering binding properties and signaling capacity

The tissue-specific expression of these variants suggests specialized functions in different microenvironments. Research approaches for studying these variants include RT-PCR to detect specific transcripts, Western blotting with domain-specific antibodies, and functional assays comparing signaling properties .

What are the critical factors to consider when working with recombinant FCAR?

When designing experiments with recombinant FCAR, researchers should consider:

• Expression system: Recombinant FCAR can be produced in various systems including Sf9 insect cells and mammalian cells, each yielding proteins with potentially different post-translational modifications

• Protein tags: Most commercial preparations include C-terminal tags (e.g., 6-His tag) for purification and detection purposes

• Formulation: Typically lyophilized from PBS solutions and requiring reconstitution at specific concentrations (e.g., 100-500 μg/mL)

• Storage conditions: Addition of carrier proteins (e.g., 0.1% HSA or BSA) may enhance stability for long-term storage

• Binding kinetics: Functional recombinant FCAR should demonstrate binding affinity to IgA with KD values <10 nM for research applications

Adequate controls should include parallel testing with other Fc receptors and validation of activity through binding assays with monomeric and polymeric IgA .

How can FCAR-expressing cells be generated for in vitro studies?

Methodological approaches for generating FCAR-expressing cells include:

• Transfection of cell lines: Human cell lines (e.g., HEK293, U-937, HL-60) can be transfected with FCAR expression constructs

• Co-expression with FcR γ-chain: For functional signaling, co-transfection with FcR γ-chain is essential as FCAR requires this association for signal transduction

• Primary cell isolation: Neutrophils and monocytes naturally expressing FCAR can be isolated from human blood using density gradient centrifugation

• Cytokine treatment: Treatment with recombinant IFN-γ can significantly increase Fc receptor expression on monocytes and may upregulate FCAR

• Verification methods: Flow cytometry with anti-CD89 antibodies or fluorescently-labeled IgA to confirm surface expression and binding capacity

Successful FCAR expression should be verified both at the protein level (Western blot, flow cytometry) and functionally through binding assays and downstream signaling analysis .

What binding assays can effectively measure FCAR-IgA interactions?

Several methodological approaches can be employed to assess FCAR-IgA interactions:

• Surface Plasmon Resonance (SPR): Provides real-time binding kinetics and affinity measurements (KD) between recombinant FCAR and various forms of IgA

• Flow cytometry: Using fluorescently-labeled IgA (e.g., Alexa Fluor 647-conjugated) to measure binding to FCAR-expressing cells

• ELISA-based methods: Immobilizing either FCAR or IgA and detecting binding with specific antibodies

• Cellular activation assays: Measuring functional outcomes of FCAR engagement such as calcium flux, cytokine production, or phagocytosis

• Co-immunoprecipitation: To study physical association between FCAR, IgA, and signaling partners like the FcR γ-chain

These assays should be designed to distinguish between monomeric and immune complex binding, as these trigger different signaling outcomes through FCAR .

How is FCAR implicated in autoimmune and inflammatory diseases?

FCAR has dual roles in inflammatory disease pathogenesis:

• IgA Nephropathy (IgAN): Polymorphisms in the FCAR promoter region (-114C/C) show significantly increased incidence in IgAN patients compared to those with other chronic kidney diseases (15.6% vs. 4.0%) and healthy donors (15.6% vs. 2.4%)

• Circulation of FCAR complexes: Shedding and circulation of polymeric IgA/FCAR immune complexes has been observed in inflammatory conditions

• Dual signaling effects: While sustained FCAR aggregation promotes inflammatory responses, monomeric IgA binding to FCAR can inhibit IgG or IgE-induced degranulation, suggesting a protective role in certain contexts

• Allelic variations: Like FcγRIIA polymorphisms that influence rheumatoid arthritis susceptibility, FCAR variations may predispose individuals to specific autoimmune conditions

The complex interplay between FCAR's pro-inflammatory and anti-inflammatory functions contributes to disease pathogenesis in tissues where IgA immune complexes accumulate .

What therapeutic approaches target FCAR for inflammatory diseases?

Several therapeutic strategies targeting FCAR are being investigated:

• Harnessing ITAMi signaling: Designing molecules that engage FCAR in ways that preferentially trigger inhibitory signaling to suppress inflammation

• Blocking pathogenic interactions: Developing antagonists that prevent IgA immune complex binding to FCAR

• Targeting Src family kinases: Modulating the kinases that control the switch between inhibitory and activating FCAR signaling

• Exploiting receptor downregulation: Methods to induce FCAR internalization or shedding to reduce surface availability

• Recombinant soluble FCAR: Potential use as decoys to capture IgA immune complexes before they can engage cell-surface FCAR

These approaches aim to tip the balance of FCAR signaling toward anti-inflammatory outcomes while preserving beneficial aspects of IgA-mediated immunity .

What are the implications of FCAR's absence in mouse models?

The absence of a direct FCAR ortholog in mice presents significant challenges for research:

• Translational barriers: Standard mouse models cannot directly recapitulate human IgA-FCAR interactions, limiting translational research

• Alternative approaches: Researchers must use transgenic mice expressing human FCAR, humanized mouse models, or ex vivo human cell systems

• Evolutionary insights: This species difference suggests that IgA-mediated immunity evolved differently between humans and mice

• Related receptors: The murine paired Ig-like receptor-A (PIR-A) shares sequence similarity with human FCAR but does not function as an IgA receptor

• Non-human primates: May provide more relevant models for studying FCAR biology in vivo

These considerations are crucial when designing experiments to study FCAR function or when developing FCAR-targeted therapeutics that must eventually be tested in vivo .

How does FCAR compare structurally and functionally across species?

FCAR shows variable conservation across different species:

These cross-species differences reflect evolutionary adaptation of IgA-mediated immunity to different ecological niches and immune challenges . Researchers should consider these variations when selecting animal models for FCAR-related studies.